Nonetheless, some studies have indicated that chronic activation of GPR40 may be detrimental for β-cell fitness and therefore, on the contrary, GPR40 antagonists may be beneficial for T2DM treatment [15–17, 33–35]. The gene discussed is FFAR1; the disease is type 2 diabetes mellitus.